Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SoFi Technologies Inc (SOFI) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.

The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.

SoFi Technologies (SOFI) trades at $18.38, up 1.55% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong Q2 2026 results, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75–$4.85 billion, though EBITDA and earnings outlooks were maintained. The stock's valuation shows a P/E of 37.51 and P/S of 5.73, reflecting growth expectations amid profitability improvements.

The outlook for SOFI is cautiously optimistic, driven by robust member growth, cross-selling success, and a diversified revenue stream. Key opportunities include continued execution on the 'everything app' strategy and potential upside to the $19.50 consensus price target. Risks involve reliance on lending growth, pressure on Technology Platform margins, and sensitivity to Federal Reserve rate decisions. Investors should weigh strong fundamentals against high valuation multiples and competitive fintech pressures.